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SUMMARY – Th e aim of this review is to present data on bendamustine, a non-cross resistant 
alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and 
chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant 
indolent NHL and CLL in patients not fi t for conventional chemotherapy. Recent studies have shown 
superiority of bendamustine combination with rituximab (B-R) in fi rst line treatment of indolent 
NHLs and mantle cell lymphoma, suggesting a shift of the standard of care in this setting. B-R regi-
men has also shown effi  cacy in relapsed setting suggesting the possible treatment option for patients 
failing conventional chemotherapy. In rituximab-resistant NHL, the recent GADOLIN study explor-
ing the addition of obinutuzumab to bendamustine has yielded impressive result changing the stan-
dard of care in this hard-to-treat population. Concerning CLL, despite inferiority to the standard of 
care in young fi t patients, as defi ned in CLL10 study, B-R has yielded a more benefi cial toxicity profi le 
and its use in fi rst line treatment should be decided individually. In relapsed setting, the addition of 
ibrutinib to B-R has shown superior results compared to B-R alone, possibly changing the paradigm 
of treatment of relapsed CLL. In conclusion, bendamustine as a single agent or in combinations has 
shown activity with acceptable toxic profi le in the treatment of patients with indolent NHLs or CLL 
without del(17p) mutation.
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Introduction
Non-Hodgkin lymphomas (NHL) represent the 
most common malignancy in hematologic oncology. 
According to the US SEER program, its incidence is 
19.5 cases per 100 000 men and women, with 70.7% of 
patients surviving for 5 years1. Chronic lymphocytic 
leukemia (CLL) is the most common leukemia of el-
derly with the incidence of 4.6 cases per 100 000 men 
and women, with 82.6% of patients surviving for 5 
years according to the SEER program2. In Croatia, the 
incidence of NHL is estimated to 6.96 per 100 000 
men and 5.57 per 100 000 women3. Th e incidence of 
CLL is 2.59 per 100 000 men and 1.2 per 100 000 
women. It is important to note that NHLs are hete-
rogeneous disorders varying from aggressive type such 
as diff use large B cell lymphoma (DLBCL) to in dolent 
one such as follicular lymphoma (FL). In a recent 
 international classifi cation study on NHL in south-
-eastern Europe, the most common type of NHL 
was DLBCL (37%), followed by FL (20.2%)4. In this 
study, CLL was included as NHL with a prevalence 
of 12.5%.
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Bendamustine belongs to a group of alkylating 
agents, however, it has a distinct pharmacodynamic 
profi le5. In vitro, it phosphorylates tumor suppressor 
p53 leading to apoptosis. Second mechanism is DNA 
repair by upregulation of EXO1 gene leading to a base 
excision repair pathway response. Th ird mechanism is 
inducing mitotic catastrophe causing downregulation 
of several genes involved in mitotic checkpoints lead-
ing to multinucleation or micronucleation and chro-
matin condensation (all events as hallmarks of mitotic 
catastrophe). It is important to note that the mecha-
nism of bendamustine action still is not known and 
additional studies are needed to defi ne the precise 
pharmacodynamic profi le. Bendamustine also has a fa-
vorable pharmacokinetic profi le regardless of sex, age 
and race6. Concerning hepatic dysfunction, no diff er-
ence in pharmacokinetics has been found between 
normal function and mild hepatic impairment. Data 
on severe and moderate hepatic impairment are scarce, 
so caution is warranted when using bendamustine in 
this patient subpopulation. Concerning renal impair-
ment, diff erence in the safety profi le is not of clinical 
concern7. Patients with renal impairment defi ned as 
creatinine clearance <40 mL/min had only two higher 
adverse events, i.e. blood urea nitrogen and thrombo-
cytopenia. Th ese data are further supported by excel-
lent tolerability in multiple myleoma patients with re-
nal dysfunction treated by bendamustine8,9. Histori-
cally, bendamustine was fi rst synthesized and used in 
Eastern Germany during the Soviet era, but with the 
fall of the Berlin Wall, further research made it avail-
able worldwide.
Th e main aim of this review is to assess data on the 
activity of bendamustine alone or in combinations in 
NHLs and CLL.
Bendamustine as First Line Th erapy in NHL: 
the End of CHOP-R Era?
Anthracycline-based regimen in combination with 
rituximab, so called CHOP-R regimen (rituximab, 
 cyclophosphamide, doxorubicin, vincristine and pred-
nisone) has been the mainstay of treatment in CD20 
positive NHLs10-12.
Based on in vitro studies where bendamustine pro-
duced apoptotic features in cell lines of indolent lym-
phomas and synergistic activity with rituximab, it has 
been established as a possible target drug in indolent 
NHLs, especially FL13,14. First frontline study examin-
ing bendamustine in combination with rituximab (B-
R) versus CHOP-R regimen in indolent NHLs was 
performed by the Stil group for indolent lymphomas15. 
It was a phase III non-inferiority randomized clinical 
trial which included 549 patients with high tumor 
burden indolent NHLs and mantle cell lymphoma 
(MCL) randomized at a 1:1 ratio to receive either 
CHOP-R or B-R regimen for up to 6 cycles (dose of 
bendamustine 90 mg/m2 on days 1 and 2). Despite the 
non-inferiority design, improvement of progression-
free survival (PFS) favored B-R with median PFS of 
69.5 months as compared with only 31.2 months for 
CHOP-R. Additional analysis was based on histology. 
In FL, PFS in the B-R arm was not reached as com-
pared with 40.9 months in the CHOP-R arm. Inter-
estingly, B-R outperformed CHOP-R in MCL (35.4 
vs. 22.1 months), which is important since the addi-
tion of rituximab to CHOP regimen never showed 
advantages in terms of long-term outcomes in these 
patients16. However, overall survival (OS) did not dif-
fer between the groups, with median not being reached. 
One reason may have been short follow-up and small 
number of events in both arms. Another and more 
probable reason lies in the cross-over design of the 
study, i.e. the patients that progressed during or after 
CHOP-R regimen were salvaged by B-R (N=116). 
B-R was also characterized by a distinct toxicity pro-
fi le. Concerning hematologic adverse events, lower 
rates of leukopenia and neutropenia were observed 
with consequent lower rates of infectious episodes 
(37% vs. 50%). Concerning non-hematologic events, 
virtually no alopecia was observed in B-R group with 
lower rates of paresthesia, which are vincristine-in-
duced in CHOP-R protocol, and stomatitis. On the 
other hand, skin erythema and skin allergic reaction 
were more pronounced in B-R group (16% and 15%, 
respectively).
Another large study in this setting was the 
BRIGHT non-inferiority study on 447 patients com-
paring B-R (dose of bendamustine 90 mg/m2 on days 
1 and 2) to CHOP-R or CVP-R (rituximab, cyclo-
phosphamide, vincristine and prednisone) regimens in 
indolent NHLs or MCL, up to 6 cycles with addi-
tional 2 cycles permitted per investigator discretion17. 
Primary objective was complete response (CR) as 
measured by the “revised response criteria for malig-
nant lymphoma”18. CR response was achieved in 31% 
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of B-R group compared to 25% in CHOP-R/CVP-R 
group, although the diff erence was not statistically sig-
nifi cant. Overall response rate (ORR) was similar be-
tween the groups (97% and 91%, respectively). In fur-
ther analysis, all variables favored B-R regimen with 
MCL being once again the most prominent one. Con-
cerning safety profi le, B-R regimen produced fewer 
hematologic adverse events, primarily, leukopenia, neu-
tropenia and lymphocytopenia. Th e rates of infections 
were similar between the groups. Once again, B-R did 
not cause alopecia. Drug hypersensitivity was noted in 
B-R group, mainly in the form of skin reactions, but 
this toxicity was manageable. At the time of writing 
this review, no data on PFS and OS in the BRIGHT 
study were available. Interestingly, B-R regimen was 
better tolerated than CHOP-R or CVP-R as mea-
sured by quality of life (QoL) questionnares19. Patients 
reported improved outcomes on many scales such as 
cognitive, physical, social and emotional functioning, 
indicating major QoL improvement in patients receiv-
ing B-R.
In conclusion, B-R has demonstrated equal or bet-
ter eff ect to the standard of care, improvement in out-
comes in terms of PFS, major improvement in MCL 
histology, distinct but favorable toxicity profi le, and 
better tolerability. Th is has led some authors to declare 
the end of the CHOP-R era in indolent lymphomas20. 
Th e results of these two studies are summarized in 
Table 1.
However, despite these encouraging results, regula-
tory agencies did not recognize B-R as a standard of 
care in indolent NHLs or MCL21,22. In the USA, 
bendamustine is approved for rituximab resistant in-
dolent NHL, whereas in the European Union (EU) 
only some countries such as Germany or the United 
Kingdom have approved it for fi rst line treatment of 
indolent NHLs. In Croatia, bendamustine is approved 
for rituximab-resistant indolent NHLs23. In accor-
dance with the leading guidelines and data from two 
phase III randomized controlled trials, B-R should 
become standard of care in the treatment of indolent 
NHLs, especially for MCL patients who are not fi t for 
high dose chemotherapy24-26. Despite this regulatory 
limitation, B-R is slowly but steadily entering clinical 
practice all over the world, replacing the CHOP-R 
regimen in indolent NHLs.
However, none of the pivotal studies had mainte-
nance strategy with rituximab in protocol. Mainte-
nance with rituximab every 2 months in case of CR or 
partial remission (PR) has become the standard of care 
in Europe based on PRIMA results showing improved 
3-year PFS of 74.9% in maintenance group compared 
with 57.6% in observation group27. To address this 
question, the MAINTAIN trial was designed28. Th is 
was a phase III trial with three arms comparing ritux-
imab maintenance for 2 years, 4 years, and observation 
after B-R induction. Th is approach showed feasibility 
and no safety signal was noted in preliminary analy-
sis29. However, initial results in subset analysis of 120 
MCL patients were disappointing30. After median 
follow-up of 54.2 months, two groups did not diff er in 
PFS (not reached vs.54.7 months) or OS. Th e authors 
conclude that the follow-up was too short to present 
defi nitive results. Until then, maintenance strategy fol-
lowing B-R in indolent NHLs or MCL is purely ex-
perimental.
Furthermore, in the era of B cell receptor (BCR) 
signaling, B-R is attractive backbone regimen for 
combinations with this inhibitor. Yet, we have learnt a 
lesson in a hard way with idelalisib, a PI3Kδ inhibitor 
approved for refractory indolent NHLs31. In fi rst line 
setting, it was combined with B-R in the treatment of 
indolent NHLs or CLL. Despite excellent response 
rates, the studies were terminated due to unexpected 
toxicity aff ecting survival curve (cytomegalovirus reac-
tivation, Pneumocystis jirovecii infections, colitis, trans-
Table 1. Results of non-inferiority studies comparing B-R regimen and conventional chemotherapy in indolent NHLs 
or MCL
Author Phase B dose (mg/m2) Arm N Primary outcome Secondary outcome
Rummel15 III 90 B-R vs. CHOP-R 549 PFS 69.5 months 
vs. 31.2 months
ORR 93% vs.91%*
Flinn17 III 90 B-R vs. CHOP-R /CVP-R 447 CR 31% vs. 25%* ORR 97% vs. 91%*
*nonsignifi cant; NHL = non-Hodgkin lymphoma; MCL = mantle cell lymphoma; B-R = bendamustine-rituximab; B=bendamustine; PFS 
= progression-free survival; CR = complete remission; ORR = overall response rate
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aminitis, and pneumonitis)32. Th is should serve as a 
warning that combination therapy with BCR inhibi-
tors should not be taken lightly.
Concerning DLBCL, to our knowledge, there is no 
published study evaluating B-R in fi rst line setting, al-
though a phase II trial is ongoing evaluating feasibility 
of this approach in elderly patients with previously un-
treated DLBCL33.
Bendamustine in Relapsed Setting
Indolent NHLs or MCL
Th ere is only one randomized phase III trial evalu-
ating B-R (dose 90 mg/m2) versus fl udarabine based 
regimen (FR, dose of fl udarabine 25 mg/m2 on day 
1-3)34. Th e study included 219 patients with indolent 
NHLs or MCL, randomized at a 1:1 ratio. Th e pri-
mary objective was PFS, favoring B-R regimen with 
34.2 months compared to only 11.7 months in F-R 
group. Th e authors demonstrated better OS for B-R 
group (109.7 months and 49.1 months, respectively). 
B-R and F-R had a similar toxicity profi le, myelosup-
pression and infections. Th e importance of this trial is 
that B-R was highly active in relapsed setting and 
could be used as a retreatment strategy in relapsed or 
refractory indolent NHLs and MCL25. Other single 
arm trials evaluating B-R regimen in this setting are 
summarized in Table 2.
In conclusion, B-R regimen is a viable option in 
the treatment of patients with relapsed indolent NHLs 
and MCL not fi t for stem cell transplant with high 
ORR rates, adequate duration of response and man-
ageable toxicity.
Th ere are multiple trials under way exploring addi-
tion of other agents such as lenalidomide, bortezomib, 
duvelisib (dual PI3Kδ and γ inhibitor) or temsirolimus 
to enhance the activity of B-R regimen itself39-42.
Bendamustine in rituximab-refractory indolent NHL
Eventually, a signifi cant proportion of patients will 
develop refractoriness to rituximab defi ned as stable 
disease (SD) or progressive disease (PD) after ritux-
imab therapy or progression during the fi rst 6 months 
after completion of therapy. Traditionally, these pa-
tients had poor outcomes and represented clinical 
challenge for treatment strategy.
One study explored bendamustine (dose 120 mg/
m2) in 76 patients with rituximab-refractory indolent 
or transformed NHL43. Th e proportion of patients 
with transformed NHL was 20%. ORR for the whole 
group was 77% with 34% CR. ORR for indolent 
NHLs was 82% with 17 CR and median PFS of 8.25 
months. However, duration of response in transformed 
NHLs was much shorter with PFS being only 4.18 
months.
Th e pivotal study in this area was conducted by 
Kahl et al. including 100 patients with rituximab-re-
sistant NHLs44. Th e median number of previous ther-
apies was 2 with 36% of patients being refractory to 
previous therapy. Bendamustine was administered as a 
single agent at a dose of 120 mg/m2 on days 1 and 2 for 
up to 8 cycles. ORR for the whole group was 77%. 
Interestingly, bendamustine produced high-level re-
sponse in chemorefractory group (ORR=64%) and al-
kylator-refractory group (ORR=60%) due to its non-
cross resistant properties. However, duration of re-
sponse was rather short being 9.2 months with median 
PFS of 9.3 months. Th is study led to approval of 
bendamustine under current designation in the USA 
and Croatia21,23. Recently, great breakthrough was 
achieved in this setting with results of the GADOLIN 
study45. Th is phase III trial explored whether the addi-
tion of obinutuzumab, a type II antiCD20 antibody, to 
bendamustine (90 mg/m2 on day 1 or 2) followed by 
maintenance was superior to bendamustine alone. It 
should be noted that the design of the study was un-
balanced since patients in the comparator arm received 
bendamustine in a dose of 120 mg/m2 on day 1 or 2. A 
Table 2. Phase II studies on B-R regimen in relapsed 









Rummel35 II 90 63 ORR 90% PFS 24 
months
Robinson36 II 90 67 ORR 92% PFS 24 
months
Weide37* II 90 57 ORR 89% PFS 19 
months
Visco38** II 70 20 ORR 80% 2-year 
PFS 70% 
*addition of mitoxantrone to B-R regimen; **only MCL patients; 
NHL = non-Hodgkin lymphoma; MCL = mantle cell lymphoma; 
B = bendamustine; R = rituximab; ORR = overall response rate; 
PFS = progression-free survival
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total of 396 patients were randomized at the 1:1 ratio. 
Despite similar ORR between the groups (69.1% vs. 
63%), PFS was signifi cantly diff erent and not reached 
in G-B group compared to 14 months in B group after 
median follow-up of 20 months. Th is effi  cacy of G-B 
regimen to produce lasting responses may be attribut-
ed to eradication of minimal residual disease (MRD)46. 
In subanalysis of 93 patients, eradication of t(14;18), a 
pathognomonic event in FL, was associated with im-
proved outcome, with 82% of patients achieving nega-
tivity in G-B group compared to 43% of patients in B 
group. PFS in patients that achieved MRD negativity 
in G-B group was not reached as compared with 7.6 
months in B group. Outcomes of MRD positive pa-
tients were poor regardless of the treatment arm, with 
PFS of 5.4 months in G-B group and 3 months in B 
group. Th e GADOLIN trial subsequently led to ap-
proval of obinutuzumab in combination with benda-
mustine for rituximab-refractory indolent NHLs47. It 
is important to note that this drug has not yet been 
approved in the EU for this indication48. Th e studies 
are summarized in Table 3. Owing to excellent out-
comes in rituximab-resistant indolent NHLs, the G-B 
regimen might be included in the standard of care of 
this hard-to-treat population.
not candidates for high dose chemotherapy and the 
standard of care remains elusive in this population51. 
Owing to its properties, mainly as alkylator non-cross 
resistant and favorable toxicity profi le, bendamustine 
may be the drug of choice in this setting. Several phase 
II trials evaluated the activity of B-R regimen in re-
lapsed or refractory DLBCL. Th e largest trial included 
69 patients receiving B-R (dose of bendamustine 120 
mg/m2 on day 1 or 2)52. Th e ORR was high (62.7%) 
with 37.3% of CR, but the response did not translate 
in PFS, which was only 6.7 months. All published 
studies on B-R regimen in relapsed or refractory 
DLBCL are summarized in Table 4.









Friedberg43 II 120 76 ORR 82% PFS 8.25 
months
Kahl44 II 120 100 ORR 77% PFS 9.3 
months
Sehn 45 III 120 
(G-B) 
/90 (B)






NHL = non-Hodgkin lymphoma; G-B = obinutuzumab-benda-
mustine; B = bendamustine; ORR = overall response rate; PFS = 
progression-free survival






















90/120 28 ORR 50% PFS 8 
months
DLBCL = diff use large B cell lymphoma; ORR = overall response 
rate; PFS = progression-free survival
Is there a role for bendamustine 
in relapsed or refractory DLBCL?
In young fi t patients with relapsed or refractory 
DLBCL, high dose chemotherapy combined with 
rituximab followed by ASCT represents a standard of 
care49,50. However, a signifi cant subset of patients are 
In conclusion, there are limited data on B-R activ-
ity in relapsed or refractory DLBCL. B-R regimen 
results in relatively high ORR, but long term outcomes 
are poor. Th is regimen should be off ered to a limited 
number of patients in whom more aggressive therapy 
is not a valid option due to comorbidities. Further-
more, this regimen based on data from phase II trials 
should not be pursued further in the treatment of 
DLBCL, especially in the era of BCR inhibitors55.
Bendamustine in CLL
Bendamustine in the treatment of CLL; 
fi rst line setting
Due to demonstration of in vitro effi  cacy of benda-
mustine in CLL cell lines, it has become an attractive 
agent in the treatment of CLL56. Th e pivotal study in 
this area is comparison of bendamustine (100 mg/m2 
on days 1 and 2) to chlorambucil (0.8 mg/kg on days 1 
and 15) in 319 patients for up to 6 cycles57. Primary 
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objective was ORR achieved in 68% in B arm com-
pared to 31% in Chl arm. Higher rates of CR were 
noted in patients treated with B (31% and 2%, respec-
tively). Th is advantage translated in the improvement 
of PFS with median PFS of 21.6 months in B arm 
compared to only 8.3 months in Chl arm. Concerning 
safety profi le, B arm was associated with more toxicity, 
mainly skin allergic reaction, but hematologic toxici-
ties were also more pronounced, resulting in a higher 
frequency of severe infections (8% vs. 3%). Updated 
results with a median follow-up of 54 months did not 
show OS benefi t when stratifying patients according 
to age or CLL stage58. However, in the analysis accord-
ing to objective response, median OS was not reached 
in B group compared to 68.3 months in Chl group. 
Th ese results led to approval of bendamustine use in 
CLL in fi rst line setting in patients who are not able to 
tolerate the FCR (fl udarabine, cyclophosphamide, 
rituximab) regimen21,23.
Based on in vitro studies and activity in indolent 
NHLs, the question arises if bendamustine could be 
the backbone chemotherapy in combination with 
rituximab14. Th e preliminary data come from phase II 
trial on 117 patients with untreated CLL59. B-R (dose 
90 mg/m2 on days 1 and 2) resulted in impressive 
ORR of 88% with 23.1% of CR. Th e median event-
free survival (EFS) was 33.9 months with the majority 
of patients being alive at the end of follow-up. How-
ever, we must note that ORR (37.5%) was lower in 
patients harboring ominous del(17p), indicating that 
B-R is not an appropriate regimen for this subpopula-
tion. Th ere is an ongoing phase III MaBLe study com-
paring B-R to R-Chl, for which defi nitive results were 
not available at the time of writing this review60.
Yet, due to the fact that bendamustine was com-
pared to chlorambucil, a ‘sick young puppy’ as the 
world renowned expert Bruce Cheson would call it, 
comparison with FCR, the standard of care in young, 
fi t patients without del(17p) was needed61,62. To ad-
dress this question, the CLL 10 study was designed 
including 561 young fi t patients without del(17p) as 
non-inferiority study comparing B-R (dose 90 mg/m2 
on days 1 and 2) to FCR for up to 6 cycles63. Primary 
endpoint was PFS of 41.7 months in B-R compared to 
55.2 months in FCR group, indicating that B-R was 
inferior in this setting. ORR was similar between the 
groups (95% vs. 96%), with a higher rate of CR in 
FCR group (31% vs. 96%). However, the treatment 
with FCR comes with multiple adverse events, mainly 
hematologic toxicities, leading to a greater rate of in-
fections (77% vs. 65%). Furthermore, FCR causes pro-
longed myelosuppression with the possibility of late 
infections after completion of therapy64. Another safe-
ty signal in FCR is the occurrence of secondary malig-
nancies with a 2.38 risk to develop therapy-related 
acute myelogenous leukemia or myelodysplastic syn-
drome (5.1%) or Richter transformation to DLBCL 
(9%)65. Both entities are associated with dismal out-
comes.
In our opinion, despite being inferior to FCR, B-R 
regimen should be introduced in the real-world clini-
cal setting. Th e basis of treatment should be made 
upon specifi c goals and patient comorbidities, i.e. the 
choice of B-R regimen should be made individually in 
fi rst line setting of CLL.
Recently, feasibility of obinutuzumab in combina-
tion with FC (fl udarabine, cyclophosphamide) or 
bendamustine in a dose of 90 mg/m2 (G-B) was ex-
plored in the Galton phase IB study66. Th e number of 
patients in G-B group was 20 with impressive ORR of 
90% with 20% CR and 25% CR with incomplete mar-
row recovery. After median follow-up of 23.5 months, 
none of the patients progressed or died. Th e safety pro-
fi le was manageable with most prominent adverse ef-
fect being infusion related reaction in 90% of patients, 
occurring primarily at fi rst G-B cycle. Based on the 
effi  cacy of this regimen, a phase II trial is currently 
ongoing evaluating G-B in previously untreated 
CLL67.
Bendamustine was also investigated in combina-
tion with ofatumumab, human antiCD20 antibody 
leading to cell lysis and antibody-dependent cell-me-
diated cytotoxicity68. Th is drug was fi rstly approved in 
the EU for the treatment of patients refractory to 
fl udarabine and alemtuzumab 69. In a study on 40 pre-
viously untreated patients unsuitable for FCR chemo-
therapy, the ORR was 95% with 43% CR70. Toxicity 
profi le was tolerable with infusion reactions being the 
most common adverse event. Th e pivotal study in this 
area is the OMB11 5991 study on 44 patients not fi t 
enough for FCR regimen69. ORR was 95% with 43% 
CR. It is important to note that more than half of the 
patients achieved MRD negativity, i.e. B-R can achieve 
molecular response. Th is led to approval of this regi-
men in patients who are not fi t enough to tolerate 
FCR protocol68. However, we must note that due to 
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the clear superiority of rituximab and its worldwide 
use, ofatumumab is rarely used in clinical practice and 
the real impact of these regimens in everyday use re-
mains unknown. Th e results of studies described above 
are summarized in Table 5.
Bendamustine in the treatment of CLL; 
relapsed setting
Th e earliest trial in this setting was a dose fi nding 
trial in 15 patients with relapsed or refractory CLL71. 
Th e maximum tolerated dose was 110 mg/m2 and the 
recommended dose was 100 mg/m2 at four-week in-
terval. Th e activity was promising with nine patients 
responding to treatment including 4 CRs. During the 
15-month follow-up, only one patient relapsed. Th e 
authors concluded that this regimen was active and 
tolerable in heavily pretreated CLL and should be in-
vestigated further on a larger number of patients.
A larger phase II study included 78 patients treated 
with B-R regimen (dose 70 mg/m2 on day 1 or 2)72. 
ORR was 50% with 9% CR and 47.4% PR. In sub-
group analysis, patients with del(17p) had the worst 
outcome with ORR being only 7.1%. It is important 
to note that ORR was high in fl udarabine-resistant 
patients (45.5%). Th e median EFS was 14.7 months 
after 24-month follow-up. Th e median OS was 33.9 
months. Th e regimen was associated with more toxic-
ity than in the fi rst line setting. Th e adverse events of 
concern were severe infections that occurred in 12.8% 
of patients, but this toxicity profi le is expected in heav-
ily pretreated patients.
In the Italian phase II trial, 47 patients were en-
rolled receiving bendamustine (dose 70 mg/m2 on day 
1 or 2) in combination with ofatumumab for up to 6 
cycles73. B-O regimen resulted in ORR of 72.3% with 
17% CR. It also yielded somewhat better ORR of 30% 




Arm N Primary outcome Secondary outcome
Knauf57 III 100 B vs. Chl 319 ORR 68% vs. 31% Median PFS 21.6 vs. 8.3 months
Fischer59 II 90 B-R 117 ORR 88% Median EFS 33.9 months
Eichhorst63 III 90 B-R vs. FCR 561 Median PFS 41.7 
vs. 55.2 months
ORR 95% vs.96%
Brown66 I 90 G-B 20 ORR 90% NA
Off ner70 II 90 O-B 40 ORR 95% NA
OMB11
599169
II 90 O-B 47 ORR 95% MRD negativity 56%
CLL = chronic lymphocytic leukemia; B = bendamustine; Chl=chlorambucil; B-R = bendamustine-rituximab; FCR = fl udarabine, cyclo-
phosphamide, rituximab; G-B = obinutuzumab-bendamustine; O-B = ofatumumab-bendamustine; ORR = overall response rate; PFS = 
progression-free survival; EFS = event-free survival; NA = not applicable; MRD = minimal residual disease




Arm N Primary outcome Secondary outcome
Lissitchkov71 I 100 B-R 15 ORR 60% NA
Fischer72 II 70 B-R 78 ORR 50% EFS 14.7 months
OS 33.9 months
Cortelezzi73 II 70 B-O 47 ORR 72.3% 2-year OS 83.6%
2-year PFS 49.6%
Chanan-Khan74 III 70 B-R+ibrutinib
B-R 
578 Median PFS not reached 
vs. 13.3 months
ORR 83% vs. 68%
CLL = chronic lymphocytic leukemia; B = bendamustine; B-R = bendamustine-rituximab; B-O = bendamustine-ofatumumab; ORR = 
overall response rate; PFS = progression-free survival; OS = overall survival; EFS = event-free survival; NA = not applicable
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in del(17p) subgroup. After median follow-up of 24.2 
months, 2-year OS and PFS rates were 83.6% and 
49.6%, respectively.
However, most interesting is the addition of ibruti-
nib, an oral Bruton kinase inhibitor to B-R regimen in 
the phase III Helios study74; 578 patients were as-
signed to receive either placebo or ibrutinib in addition 
to B-R (dose 70 mg/m2 on day 1 or 2) for up to 6 cy-
cles. Ibrutinib was administered until disease progres-
sion or unacceptable toxicity. Th e main objective was 
PFS, which was not reached in ibrutinib group as 
compared with 13.3 months in placebo group. ORR 
was higher in ibrutinib group (83% vs. 68%). In post hoc 
analysis, all variables favored ibrutinib treatment. Th e 
addition of ibrutinib did not result in additional safety 
signals. One of the possible pitfalls of the study was 
not including patients with del(17p) for which ibruti-
nib has become the standard of care75-77.
In conclusion, B-R regimen seems like a reasonable 
option in patients failing FCR. Concerning the addi-
tion of ibrutinib to B-R, we must wait for reaction of 
regulatory agencies, i.e. whether ibrutinib will be reg-
istered in combination with B-R for the treatment of 
relapsed or refractory CLL. All the studies are sum-
marized in Table 6.
Conclusion
As shown above, bendamustine alone or in combi-
nations with other agents has shown impressive activ-
ity in indolent NHLs, MCL and CLL without 
del(17p). We must highlight certain combinations 
which may be a standard of care in various settings of 
these diseases, as follows:
1. B-R for fi rst line setting in indolent NHLs or 
MCL,
2. G-B for rituximab-resistant indolent NHLs,
3. B-R for selected patients with CLL without 
del(17p), and
4. B-R in combination with ibrutinib for relapsed 
CLL without del(17p).
However, we are in the era of BCR pathway in-
hibitors, so the question arises whether bendamustine 
is still relevant while pursuing the ‘chemo-free’ era. 
However, these agents have shown unexpected toxici-
ties, especially in fi rst line setting, leading to early ter-
mination of multiple trials and causing ‘speed bumps’ 
on our way to ‘chemo-free’ era78. Until we learn how to 
combine these inhibitors with acceptable toxicity pro-
fi le, bendamustine will remain relevant in every day 
hematologic practice.
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STARI LIJEK U NOVOJ ERI ZA BOLESNIKE S NE-HODGKINOVIM LIMFOMIMA 
I KRONIČNOM LIMFOCITNOM LEUKEMIJOM
M. Bogeljić Patekar, V. Milunović, K. Mišura Jakobac, D. Perica, I. Mandac Rogulj, M. Kursar, 
A. Planinc-Peraica i S. Ostojić Kolonić
Cilj ovoga preglednog rada je procijeniti aktivnost bendamustina te njegovih kombinacija u ne-Hodgkinovim limfomima 
(NHL) i kroničnoj limfocitnoj leukemiji (KLL). Bendamustin je sada indiciran u Republici Hrvatskoj za liječenje rituksi-
mab-rezistentnog NHL-a i u bolesnika s KLL-om koji nisu kandidati za konvencionalnu terapiju. No, kombinacija benda-
mustina s rituksimabom (B-R) u prvoj liniji terapije indolentnog NHL-a i limfoma plaštene zone pokazala se boljom od 
konvencionalne kemoterapije pa bi B-R trebao postati zlatni standard u prvoj liniji liječenja ovih limfoma. Protokol B-R 
 također ima aktivnost u relapsnom indolentnom NHL-u te predstavlja opciju za bolesnike koji su progredirali nakon kon-
vencionalne kemoterapije. U rituksimab-rezistentnom NHL-u nedavna studija GADOLIN koja je proučavala dodatak 
 obinutuzumaba bendamustinu pokazala je jasnu superiornost prema bendamustinu i promijenila zlatni standard u ovoj 
 populaciji zahtjevnoj za liječenje. U KLL-u usprkos inferiornosti B-R prema FCR-u u studiji CLL10 B-R je bio obilježen 
boljim profi lom toksičnosti te se može ponuditi pojedinim bolesnicima na temelju individualizirane odluke. U relapsnom 
okružju KLL-a dodatak ibrutiniba protokolu B-R pokazao je superiornost prema B-R s mogućom promjenom paradigme 
liječenja ovih bolesnika. Zaključno, bendamustin sam ili u kombinacijama pokazao je visoku aktivnost s povoljnim toksičnim 
profi lom u liječenju indolentnih NHL-a i KLL bez mutacije del(17p).
Ključne riječi: Bendamustin hidroklorid; Alkilirajuća sredstva; Limfom, ne-Hodgkinov; Rituksimab; Leukemija B-stanica, 
limfocitna; Obinutuzumab
